Browsing Tag
Nifty Pharma
1 post
Biocon (NSE: BIOCON) gains EU nod for Denosumab biosimilars Vevzuo and Evfraxy to target bone health market
Biocon Biologics receives EU approval for Denosumab biosimilars Vevzuo and Evfraxy. Find out how this milestone could reshape its European biosimilars strategy.